转运体介导药物相互作用的临床要点
本文综述转运体介导的药物相互作用(DDI)在药物处置与效应中的作用。肠道P-糖蛋白、肝细胞OATP1B1及肾近端小管OCT2/MATE1/MATE2-K等转运体可改变底物药血浆浓度,并可能影响局部组织浓度与毒性。新药研发中已常规开展体外转运体筛查并在必要时进行健康志愿者DDI研究,但老年人多重用药伴肝肾功能受损等临床意义仍待明确。
要点
- 转运体DDI可改变底物药血浆浓度及肝、肾局部组织浓度与毒性。
- 肠道P-gp、肝OATP1B1、肾OCT2/MATE1/MATE2-K是主要介导转运体。
- 新药研发需体外筛查转运体底物/抑制剂,必要时行健康志愿者DDI研究。
核心结论
- 转运体介导的DDI可改变底物药血浆浓度及局部组织浓度,进而可能影响疗效与毒性。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 肠道P-糖蛋白、肝细胞OATP1B1及肾近端小管OCT2/MATE1/MATE2-K等转运体介导的DDI可改变底物药血浆浓度。
- 转运体介导的DDI还可改变肝、肾等局部组织浓度,并可能改变效应或毒性。
- 新药研发中已对候选分子开展转运体底物与抑制剂的体外筛查,必要时在健康志愿者中进行DDI研究。
临床怎么用
- 临床对转运体底物药联用时,应关注肠道、肝脏及肾脏转运体介导的DDI风险。
- 老年人多重用药且伴肝或肾功能受损时,转运体DDI的临床意义需特别关注。
局限性
- 转运体DDI在老年人多重用药伴肝肾功能受损人群中的临床意义尚未解决。
- 减少转运体DDI能在多大程度上改善真实世界用药安全仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug transporters play an essential role in disposition and effects of multiple drugs. Plasma concentrations of the victim drug can be modified by drug-drug interactions occurring in enterocytes (e.g., P-glycoprotein), hepatocytes (e.g., organic anion-transporting polypeptide 1B1 (OATP1B1)), and/or renal proximal tubular cells (e.g., organic cation transporter 2 (OCT2)/multidrug and toxin extrusion 1 and 2-K (MATE1/MATE2-K)). In addition, transporter-mediated drug-drug interactions can cause altered local tissue concentrations and possibly altered effects/toxicity (e.g., in liver and kidneys). During drug development, there is now an intensive in vitro screening of new molecular entities as transporter substrates and inhibitors, followed if necessary by drug-drug interaction studies in healthy volunteers. Nevertheless, there are still unresolved issues, which will also be discussed in this review article (e.g., the clinical significance of transporter-mediated drug-drug interactions of particular relevance to the elderly who are prescribed multiple drugs, with additional impaired liver or kidney function, and the extent to which medication safety in real life could be improved by a reduction of those interactions).
引用
- Gessner A, König J, Fromm MF, et al. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin Pharmacol Ther. 2019. PMID: 30648735. doi:10.1002/cpt.1360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。